A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Phase of Trial: Phase III
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Ubrogepant (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Allergan
- 20 Jun 2017 Planned number of patients changed from 1350 to 1650.
- 08 Sep 2016 Status changed from not yet recruiting to recruiting.
- 19 Aug 2016 New trial record